Evidence map›Paper›PMID 39673636›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Immunomodulatory activity of metoclopramide HCl on murine macrophages.

Esra Aydemir

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Esra AydemirDepartment of Biomedical Engineering, Biruni University, Istanbul, 34010, Turkey. eaydemir@biruni.edu.tr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metoclopramide HCl is the active ingredient of the commonly used drugs against nausea, heartburn, and acid reflux. Other than the patients with the acid reflux and stomach problems, it has been widely used in patients going through chemotherapy and radiotherapy, as well as patients suffering from migraine with stomach issues. To our knowledge, the immunomodulatory effect of metoclopramide HCl has never been tested extensively. Since patients who are going through chemotherapy and radiotherapy are prone to developing immunodeficiencies, it is imperative to analyze the activity of this active drug ingredient on the mammalian macrophages. For this purpose, the mammalian macrophages were tested for their potential to produce the pro-inflammatory cytokines, in vitro, in the presence and absence of LPS as the stimulating agent with a range of metoclopramide concentrations. Our results suggest that metoclopramide HCl did not stimulate the macrophages by itself; but in the presence of LPS stimulation, it significantly and substantially decreased the production of the pro-inflammatory TNFα, IL-6, GMCSF, and IL12p40 cytokines. Although this study involved solely in vitro model, the results imply that in the clinical setting metoclopramide HCl might induce inflammatory reaction against potential infections.

Indexed as

Immunologic FactorsImmunomodulating AgentsMacrophagesMetoclopramideAnimalsCells, CulturedCytokinesLipopolysaccharidesMiceRAW 264.7 CellsCytokinesImmunologic FactorsImmunomodulating AgentsLipopolysaccharidesMetoclopramideAnti-inflammatory activityImmunomodulatory activityInflammationMacrophagesMetoclopramide HCl

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.